Medicine:Prostate Adenocarcinoma: TransCutaneous Hormones
The Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) study is a large randomized controlled trial in the United Kingdom of high-dose transdermal estradiol patches versus gonadotropin-releasing hormone agonist therapy in the treatment of prostate cancer in men.[1][2][3] It is specifically comparing three to four 100 μg/day estradiol patches (FemSeven or Progynova TS) against goserelin implants in approximately 2,200 men with prostate cancer.[1][4] The study was started in March 2006 and is estimated for completion in August 2021, with additional reports expected in 2023 and 2024.[1][4] Its objectives include comparison of survival, cardiovascular mortality and morbidity, pharmacological activity (e.g., suppression of testosterone levels), other side effects and toxicities, and quality of life.[1] A report on long-term cardiovascular outcomes was published in February 2021, and other reports for the study have also been published.[4] Besides the PATCH trial, the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial, also in the United Kingdom, added a high-dose transdermal estradiol patches arm with approximately 2,000 men in July 2017.[5][2][3]
References
- ↑ 1.0 1.1 1.2 1.3 "Prostate Adenocarcinoma TransCutaneous Hormones (PATCH)". U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT00303784. Retrieved 21 June 2019.
- ↑ 2.0 2.1 Gilbert, Duncan C.; Duong, Trinh; Sydes, Matthew; Bara, Anna; Clarke, Noel; Abel, Paul; James, Nick; Langley, Ruth et al. (2018). "Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform". BJU International 121 (5): 680–683. doi:10.1111/bju.14153. ISSN 1464-4096. PMID 29388336. http://discovery.ucl.ac.uk/10043138/1/Gilbert_et_al-2018-BJU_International.pdf.
- ↑ 3.0 3.1 Singla, Nirmish; Ghandour, Rashed A.; Raj, Ganesh V. (2019). "Investigational luteinizing hormone releasing hormone (LHRH) agonists and other hormonal agents in early stage clinical trials for prostate cancer". Expert Opinion on Investigational Drugs 28 (3): 249–259. doi:10.1080/13543784.2019.1570130. ISSN 1354-3784. PMID 30649971.
- ↑ 4.0 4.1 4.2 "Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme". Lancet 397 (10274): 581–591. February 2021. doi:10.1016/S0140-6736(21)00100-8. PMID 33581820. https://discovery.ucl.ac.uk/id/eprint/10121970/1/Nankivell_PATCH_CVS_paper_final_accepted_20201218.pdf.
- ↑ "Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE)". U.S. National Library of Medicine. https://clinicaltrials.gov/ct2/show/NCT00268476. Retrieved 21 June 2019.
External links
 |  |
